Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Metric
Company Name	Shionogi & Co., Ltd.
Symbol	4.51K
MSH ID	COM:SHIONOGI
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	JP
Stage
Employee Count	4.96K
Website	shionogi.com
LinkedIn
Founders

Metric
Market Cap	12.21B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.82B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.40B
EBITDA	1.23B
Operating Income	1.11B
Net Income	1.05B
EPS	3.62
Diluted EPS	3.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.87
Operating Profit Margin	0.37
EBITDA Margin	0.44
Net Profit Margin	0.37
Return on Equity	0.13
Return on Assets	0.11
Return on Capital Employed	0.13

4507

COM:SHIONOGI

Shionogi & Co., Ltd.

Last Close

2,094.50

25/11 06:45

Market Cap

1.89T

Beta: -

Volume Today

3.85M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	9.43
P/B Ratio	1.70
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.29
EV Multiple	11.86

Metric
Days Sales Outstanding	110.37
Days Payables Outstanding	85.40
Days Inventory Outstanding	403.62
Operating Cycle	522.24
Cash Conversion Cycle	445.12
Asset Turnover	0.31

Metric
Operating Cash Flow	1.00B
Free Cash Flow	817.79M
Cash Flow to Debt	50.42
Operating Cash Flow/Sales	0.37
Free Cash Flow Yield	0.07

Metric
Cash & Equivalents	2.32B
Accounts Receivable	-80.29M
Inventory	421.27M
Goodwill	99.21M
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	5.47
Quick Ratio	5.74

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.20
SG&A to Revenue	0.20